MedTrace Logo

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

NCT04488575 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-12-19

Study results available
· View outcomes & findings →

Summary

Evelo will investigate the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection

Conditions

  • Covid19

Interventions

DRUG

EDP1815

EDP1815 is an orally administered monoclonal microbe

DRUG

Placebo

Placebo oral capsule

Sponsors & Collaborators

  • Evelo Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Reynold Panettieri, MD · Rutgers, The State University of New Jersey

  • Douglas Maslin, MD · Evelo Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-26
Primary Completion
2021-05-16
Completion
2021-05-19
FDA Drug
Yes

Countries

  • United States
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04488575 on ClinicalTrials.gov